TY  - JOUR
AU  - Fernandez, Oscar
AU  - Izquierdo, Guillermo
AU  - Aguera, Eduardo
AU  - Ramo, Cristina
AU  - Hernandez, Miguel
AU  - Silva, Diego
AU  - Walker, Rob
AU  - Butzkueven, Helmut
AU  - Wang, Chenyu
AU  - Barnett, Michael
PY  - 2020
DO  - 10.1177/2055217320957358
UR  - http://hdl.handle.net/10668/19108
T2  - Multiple sclerosis journal-experimental translational and clinical
AB  - Background: Treatment of MS often begins with low-efficacy injectable disease-modifying therapy (iDMT).Objectives: To compare the effect of fingolimod 0.5 mg/day on clinical, MRI, patient-reported, and safety outcomes, in treatment-naive and...
LA  - en
PB  - Sage Publications
KW  - Beta-interferon
KW  - Clinical trial
KW  - Disease-modifying therapies
KW  - Glatiramer acetate
KW  - Outcome measurement
KW  - Relapsing/remitting
KW  - Remitting multiple-sclerosis
KW  - Reported outcome indexes
KW  - Immunomodulatory therapy
KW  - Intramuscular interferon
KW  - Subgroup analyses
KW  - Oral fingolimod
KW  - Double-blind
KW  - Disability
KW  - Efficacy
KW  - Safety
TI  - Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study
TY  - research article
VL  - 6
ER  -